Physician profile
Sindy Solomon
NPI 1750422689
$4,778.09
in general payments reported to CMS, 2019-2025
16 companies · $506 in 2025
The $506 reported for 2025 was more than what 79% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,223 · 2020: $195 · 2021: $610 · 2022: $753 · 2023: $698 · 2024: $793 · 2025: $506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,997.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,996.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $842.49 | 2019-2025 | |
| Abbvie INC. | $708.09 | 2019-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $675.08 | 2019-2024 | Stelara, Simponi, Remicade |
| Amgen INC. | $652.49 | 2019-2025 | Enbrel, Otezla, Otezla |
| Lilly USA, LLC | $565.04 | 2019-2024 | Taltz, Olumiant |
| Novartis Pharmaceuticals Corporation | $488.43 | 2019-2025 | |
| Glaxosmithkline, LLC. | $256.82 | 2019-2023 | Benlysta |
| Ucb, INC. | $173.25 | 2019-2024 | Cimzia |
| E.R. Squibb & Sons, L.L.C. | $168.17 | 2024-2025 | Orencia |
| Celgene Corporation | $118.48 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $49.00 | 2019 | |
| Genentech USA, INC. | $22.27 | 2019 | |
| Horizon Therapeutics Plc | $18.00 | 2021 | |
| Medexus Pharma, INC. | $14.75 | 2019 | |
| Hikma Pharmaceuticals USA | $14.33 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $11.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sindy Solomon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.